Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Up 22.8% in January

Harvard Bioscience, Inc. (NASDAQ:HBIO - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 654,400 shares, a growth of 22.8% from the December 31st total of 533,100 shares. Based on an average daily volume of 166,000 shares, the short-interest ratio is presently 3.9 days.

Institutional Trading of Harvard Bioscience

A number of hedge funds have recently made changes to their positions in the business. Williams & Novak LLC acquired a new stake in shares of Harvard Bioscience in the fourth quarter valued at approximately $209,000. JPMorgan Chase & Co. lifted its position in shares of Harvard Bioscience by 63.0% in the third quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier's stock valued at $79,000 after buying an additional 11,397 shares during the last quarter. Barclays PLC lifted its position in shares of Harvard Bioscience by 304.4% in the third quarter. Barclays PLC now owns 58,655 shares of the medical instruments supplier's stock valued at $157,000 after buying an additional 44,150 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Harvard Bioscience by 2.2% in the third quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier's stock valued at $2,455,000 after buying an additional 19,972 shares during the last quarter. Finally, State Street Corp lifted its holdings in Harvard Bioscience by 1.1% during the 3rd quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier's stock worth $1,930,000 after purchasing an additional 7,763 shares during the last quarter. 80.87% of the stock is owned by institutional investors and hedge funds.

Harvard Bioscience Stock Performance

Shares of HBIO traded down $0.06 during mid-day trading on Monday, reaching $1.65. The company's stock had a trading volume of 295,368 shares, compared to its average volume of 257,232. Harvard Bioscience has a 1-year low of $1.63 and a 1-year high of $4.93. The stock has a market cap of $71.97 million, a P/E ratio of -5.00 and a beta of 1.25. The business has a 50-day simple moving average of $2.07 and a two-hundred day simple moving average of $2.47. The company has a current ratio of 2.06, a quick ratio of 0.91 and a debt-to-equity ratio of 0.52.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.